Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Exchange Rate Effect (2016 - 2019)

Historic Exchange Rate Effect for Coherus Oncology (CHRS) over the last 6 years, with Q4 2019 value amounting to -$106000.0.

  • Coherus Oncology's Exchange Rate Effect fell 17681.16% to -$106000.0 in Q4 2019 from the same period last year, while for Mar 2020 it was -$140000.0, marking a year-over-year decrease of 14057.97%. This contributed to the annual value of -$276000.0 for FY2019, which is 15897.44% down from last year.
  • According to the latest figures from Q4 2019, Coherus Oncology's Exchange Rate Effect is -$106000.0, which was down 17681.16% from $59000.0 recorded in Q3 2019.
  • In the past 5 years, Coherus Oncology's Exchange Rate Effect ranged from a high of $226000.0 in Q2 2018 and a low of -$271000.0 during Q4 2016
  • Moreover, its 5-year median value for Exchange Rate Effect was -$28000.0 (2015), whereas its average is -$12100.0.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first soared by 207142.86% in 2018, then crashed by 94615.38% in 2019.
  • Quarter analysis of 5 years shows Coherus Oncology's Exchange Rate Effect stood at $82000.0 in 2015, then tumbled by 430.49% to -$271000.0 in 2016, then skyrocketed by 97.42% to -$7000.0 in 2017, then skyrocketed by 2071.43% to $138000.0 in 2018, then tumbled by 176.81% to -$106000.0 in 2019.
  • Its last three reported values are -$106000.0 in Q4 2019, $59000.0 for Q3 2019, and -$93000.0 during Q2 2019.